Taken together, the results suggest a complex interaction between MET and EGFR in NSCLC in the presence of EGFR TKIs and provide unique insight into potential resistance mechanisms and management strategies in EGFR/METex14-altered lung cancers. The gene discussed is MET; the disease is lung carcinoma.